XLXueying Li

Xueying Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xueying Li has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Effects of Helicobacter pylori on the Treatment Outcomes of Peptic Ulcer in Patients with Liver Cirrhosis: A Systematic Review and Network Meta-Analysis

    by Linhao Zhang, Jinli Lin, Xueying Li

    Background/Objectives: Helicobacter pylori (H. pylori) positivity is associated with peptic ulcers in the general population. However, its role in peptic ulcers in cirrhotic patients remains controversial. The impact of H. pylori infection status on the treatment outcomes of peptic ulcers in liver cirrhosis was investigated. Methods: A systematic review and network meta-analysis was performed. The following databases were searched: Ovid MEDLINE, PubMed, Web of Science, CQVIP, Wanfang, China National Knowledge Infrastructure, chictr.org.cn, and ClinicalTrials.gov. Relevant studies were published up to 31 December 2025. Studies comparing the treatment outcomes of peptic ulcers in liver cirrhosis were included. Patients were divided into three groups: Hp_pos group (including those who failed to eradicate H. pylori and who denied eradication therapy), Hp_neg group (H. pylori-uninfected individuals), and Hp_Erad group (H. pylori tested positive at baseline but was successfully eradicated afterwards). Prospero registration number: CRD42024551260. Results: Four prospective studies were eligible. No significant difference was found in the unhealed peptic ulcers or recurrent peptic ulcers, although the Hp_Erad group had the highest values of the surface under the cumulative ranking curve (SUCRA) [(0.773, mean rank: 1.5) and (0.809, mean rank: 1.4), respectively]. Conclusions: Based on the available low-quality evidence, this network meta-analysis did not detect a statistically significant benefit of H. pylori eradication for ulcer healing or recurrence prevention in cirrhotic patients. These findings should be interpreted as highlighting an evidence gap rather than providing definitive evidence. Further randomized controlled trials are necessary to confirm these findings. Clinical decisions regarding H. pylori eradication in cirrhotic patients should be made carefully, weighing the potential benefits against the risks.

  • Effects of Phloroglucinol on Embryo Transfer: A Systematic Review and Meta-Analysis

    by Rui Cai, Jinli Lin, Yao Liu, Linhao Zhang, Xueying Li

    Introduction: Phloroglucinol may be able to improve embryo transfer outcomes. We aimed to systematically evaluate the effects of phloroglucinol on embryo transfer outcomes. Methods: The databases searched were PubMed, Ovid MEDLINE, Web of Science, Wanfang, CQVIP, China National Knowledge Infrastructure, and ClinicalTrials.gov. The last search was on February 7, 2023. The included studies were written in English or Chinese. Randomized controlled trials and cohort studies aiming to assess the effect of phloroglucinol on embryo transfer outcomes were included. The studies reported at least one of the primary outcomes (biochemical pregnancy rate, clinical pregnancy rate, and live birth rate). The odds ratio (OR) and 95% confidence interval (CI) were calculated. A random-effects or fixed model was used where applicable to estimate the results. Results: Seventeen articles reporting 5,953 cycles were included. Biochemical pregnancy rate (OR = 1.58, 95% CI = 1.20–2.08, I2 = 71%), clinical pregnancy rate (OR = 1.69, 95% CI = 1.35–2.10, I2 = 64%), and live birth rate (OR = 1.45, 95% CI = 1.23–1.71, I2 = 36%) were improved by phloroglucinol. Less miscarriage (OR = 0.46, 95% CI = 0.35–0.60, I2 = 0%), less ectopic pregnancy (OR = 0.45, 95% CI = 0.28–0.72, I2 = 0%), higher implantation rate (OR = 1.45, 95% CI = 1.24–1.71, I2 = 62%) but more multiple pregnancy rate (OR = 1.48, 95% CI = 1.13–1.94, I2 = 0%) were induced by phloroglucinol. Endometrial peristaltic waves were improved by phloroglucinol (OR = 22.87, 95% CI = 5.52–94.74, I2 = 72%). Conclusion: Phloroglucinol may improve the outcomes of embryo transfer, including biochemical pregnancy, clinical pregnancy, and live birth rates. Further studies are warranted.


  • Effects of gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in artificial cycles: a meta-analysis

    by Xueying Li, Jinli Lin, Linhao Zhang, Yao Liu

    Purpose Gonadotropin-releasing hormone agonist (GnRHa) before artificial cycle (AC) is expected to improve pregnancy outcomes in frozen-thawed embryo transfer (FET). Many studies have explored the impact of GnRHa pretreatment of AC in FET, but the results were inconsistent. This meta-analysis was performed to systematically evaluate the effect of GnRHa pretreatment on AC in FET. Methods The last search was January 31, 2022. Randomized controlled trials and cohort studies aiming to assess the effect of GnRHa as the pretreatment of AC for endometrial preparation in FET were included. GnRHa was used before AC in the treatment group. In the control group, no pretreatment was used before AC. The eligible studies included at least one of the following outcomes: implantation, clinical pregnancy, and live birth. We calculated the odds ratio (OR) or mean difference (MD) and 95% confidence interval (CI) for each study and used a random-effects or fixed model to estimate the results. Results 27 articles (10 RCTs and 17 non-RCTs) and 14152 patients were included. AC + GnRHa improved the implantation rate (OR = 1.31, 95% CI 1.03–1.66, I2 = 79%), clinical pregnancy rate (OR = 1.27, 95% CI 1.10–1.45, I2 = 53%), and live birth rate (OR = 1.16, 95% CI 1.05–1.29, I2 = 39%). We also found that AC + GnRHa increased the implantation rate (OR = 1.35, 95% CI 1.07–1.69, I2 = 53%) and clinical pregnancy rate (OR = 1.50, 95% CI 1.12–2.01, I2 = 50%) in repeated implantation failure. In addition, AC + GnRHa was positively associated with preterm birth (OR = 1.5, 95% CI 1.15–1.94, I2 = 0%). Conclusions GnRHa pretreatment in FET can improve implantation, clinical pregnancy, and live birth rates, especially in patients with repeated implantation failure. GnRHa pretreatment seems to improve FET outcomes, though with a higher preterm birth rate.